Satsuma Pharmaceuticals

About:

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product.

Website: http://www.satsumarx.com/

Top Investors: New Enterprise Associates, RA Capital Management, SBI Investment, Wellington Management, Eventide

Description:

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.